StreetInsider.com News Articles

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: HUME DANIEL

Mon, 15 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260615/26648416.html

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: HUME DANIEL

Mon, 15 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260615/26648416.html

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Lonial Sagar

Mon, 15 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260615/26648422.html

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Lonial Sagar

Mon, 15 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260615/26648422.html

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Hoberman Kenneth

Mon, 15 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260615/26648404.html

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Hoberman Kenneth

Mon, 15 Jun 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260615/26648404.html

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Charney Laurence N

Mon, 15 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260615/26648373.html

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Charney Laurence N

Mon, 15 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260615/26648373.html

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Echelard Yann

Mon, 15 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260615/26648384.html

Form 4 TG THERAPEUTICS, INC. For: Jun 11 Filed by: Echelard Yann

Mon, 15 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260615/26648384.html

Form 8-K TG THERAPEUTICS, INC. For: Jun 11

Fri, 12 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260612/26641435.html

Form 8-K TG THERAPEUTICS, INC. For: Jun 11

Fri, 12 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260612/26641435.html

TG Therapeutics reports positive phase 1 data for BRIUMVI in myasthenia gravis

Tue, 09 Jun 2026 07:30:29 -0400

TG Therapeutics Inc. (NASDAQ: TGTX) announced positive results from a phase 1 study of subcutaneous BRIUMVI in patients with myasthenia gravis and initiated a phase 2 trial evaluating the drug as maintenance therapy.

In the phase 1 study, 82% of 11 patients with acetylcholine receptor antibody-positive myasthenia gravis achieved a minimal clinically important difference in their Myasthenia Gravis Activities of Daily Living score at week 24. The study showed a mean 4.6 point improvement in the MG-ADL score, with a median time to achieve the minimal clinically important difference of 30 days.

The patients had a mean age of 74 years and

TG Therapeutics reports positive phase 1 data for BRIUMVI in myasthenia gravis

Tue, 09 Jun 2026 07:30:29 -0400

The patients had a mean age of 74 years and

TG Therapeutics reports positive phase 1 data for BRIUMVI in myasthenia gravis

Tue, 09 Jun 2026 07:30:29 -0400

The patients had a mean age of 74 years and

TG Therapeutics reports positive phase 1 data for BRIUMVI in myasthenia gravis

Tue, 09 Jun 2026 07:30:29 -0400

The patients had a mean age of 74 years and

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

Tue, 09 Jun 2026 07:30:00 -0400